NASDAQ:SCLX Scilex (SCLX) Stock Price, News & Analysis $0.55 -0.01 (-1.78%) (As of 11/21/2024 ET) Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Scilex Stock (NASDAQ:SCLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Scilex alerts:Sign Up Key Stats Today's Range$0.55▼$0.5850-Day Range$0.56▼$1.1552-Week Range$0.54▼$2.63Volume1.38 million shsAverage Volume1.29 million shsMarket Capitalization$105.77 millionP/E RatioN/ADividend YieldN/APrice Target$11.33Consensus RatingBuy Company OverviewScilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.Read More… 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Scilex Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks69th Percentile Overall ScoreSCLX MarketRank™: Scilex scored higher than 69% of companies evaluated by MarketBeat, and ranked 343rd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingScilex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageScilex has only been the subject of 2 research reports in the past 90 days.Read more about Scilex's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Scilex are expected to grow in the coming year, from ($0.75) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Scilex is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scilex is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.50% of the float of Scilex has been sold short.Short Interest Ratio / Days to CoverScilex has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Scilex has recently decreased by 9.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldScilex does not currently pay a dividend.Dividend GrowthScilex does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.50% of the float of Scilex has been sold short.Short Interest Ratio / Days to CoverScilex has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Scilex has recently decreased by 9.21%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News SentimentN/A News SentimentScilex has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.Search Interest25 people have searched for SCLX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows10 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Scilex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $95,234.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.73% of the stock of Scilex is held by insiders.Percentage Held by Institutions69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Scilex's insider trading history. Receive SCLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter. Email Address SCLX Stock News HeadlinesJaisim Shah Purchases 32,000 Shares of Scilex Holding (NASDAQ:SCLX) StockOctober 30, 2024 | insidertrades.comScilex Holding (NASDAQ:SCLX) Director Yue Alexander Wu Acquires 20,000 SharesOctober 21, 2024 | insidertrades.comTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…November 21, 2024 | Colonial Metals (Ad)Scilex Holding Plans Merger to Boost Semnur ValueNovember 6, 2024 | markets.businessinsider.comSemnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and DenaliNovember 6, 2024 | globenewswire.comPleasing Signs As A Number Of Insiders Buy Scilex Holding StockOctober 30, 2024 | finance.yahoo.comScilex announces successful end of Phase II meeting with FDAOctober 30, 2024 | markets.businessinsider.comScilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with October 30, 2024 | globenewswire.comSee More Headlines SCLX Stock Analysis - Frequently Asked Questions How have SCLX shares performed this year? Scilex's stock was trading at $2.04 at the beginning of the year. Since then, SCLX stock has decreased by 73.0% and is now trading at $0.5515. View the best growth stocks for 2024 here. Who are Scilex's major shareholders? Scilex's top institutional investors include State Street Corp (3.90%), Janus Henderson Group PLC (0.28%), Donald L. Hagan LLC (0.07%) and XTX Topco Ltd (0.05%). Insiders that own company stock include Henry Ji, Jaisim Shah, Jay Chun, Yue Alexander Wu and Stephen Hoi Ma. View institutional ownership trends. How do I buy shares of Scilex? Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Scilex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scilex investors own include Rigetti Computing (RGTI), Pfizer (PFE), BioNTech (BNTX), Hertz Global (HTZ), Barrick Gold (GOLD), Nikola (NKLA) and BlackBerry (BB). Company Calendar Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCLX CUSIPN/A CIK1820190 Webwww.scilexholding.com Phone650-516-4310FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$11.33 High Stock Price Target$14.00 Low Stock Price Target$7.00 Potential Upside/Downside+1,923.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,330,000.00 Net Margins-233.88% Pretax Margin-233.86% Return on EquityN/A Return on Assets-111.82% Debt Debt-to-Equity RatioN/A Current Ratio0.20 Quick Ratio0.19 Sales & Book Value Annual Sales$46.74 million Price / Sales2.30 Cash FlowN/A Price / Cash FlowN/A Book Value($1.10) per share Price / Book-0.51Miscellaneous Outstanding Shares191,790,000Free Float175,048,000Market Cap$107.40 million OptionableOptionable Beta1.14 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:SCLX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Please log in to your account or sign up in order to add this asset to your watchlist. Share Scilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.